📍 The effect of Remdesivir...
The power to unlock the all time highs via Covid is systematically, within reach rather fast, due to the nature of drug prices which are inelastic. The effect of Gilead being treated as utility is heightened by DT putting the big orders in.
Compare the following two diagrams:
June 29 (Reuters) - Gilead Sciences Inc GILD on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
Remdesivir is expected to be in high demand as one of the only treatments shown to alter the course of COVID-19. After...
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the...
U.S. FDA approved Gilead Sciences Inc.’s experimental antiviral drug, remdesivir, for use as it’s showing good signs of helping hospitalised patients recover more quickly from Corona Virus.
From a Trend Analysis perspective - price action has been very choppy with lots of buying and selling in an almost Up-trending consolidation.
We expect Gilead to push...
GILD has seen positive price action YTD; due to combatting the COVID-19 with their drug Remdesivir.
Yesterday on the news, the trial on humans which was set in China to prove the effectivity of the drug, apparently "failed". However... The price just took us to the lower part of the channel , meaning the Risk-Reward-Ratio is at a good stance.
A close below...
Trade Plan for Gilead Sciences.
Will look to enter at bottom of uptrend channel (75.3) , Stop Loss once uptrend broken (74).
Target Price at 86. Potential Price at 96. Personally will take profit at resistances as insurance.
Upside for Gilead:
1a) Possible treatment for Covid-19 (Remdesivir)
1b) Possible 2nd wave of virus
2) Possible FDA approval of Arthritis...
GILD- If you didn't hear the news, yesterday Gilead labs were accredited with a drug that has been positively treating COVID19 patients. I checked the price and it is very expensive already. I had a look at the chart today and noticed that the last time this stock crossed golden (50/200 MA) on the weekly, it skyrocketed. On top of that, it held support like a...
Down to 60 / 47 up to 170 In the future.
Deepest pullback to 25 zone. Don't see it happening. This will be the first bounce off the red ribbon. Usually it is always quite strong once we touch it.
Good buy zones :
$42 - 50
Good sell zone:
$150 - 170
Gilead says that they have a coronavirus treatment in route.
The chart looks great too.
Worst case, we have a minor leg down to the .382 line, but long term I'm bullish. (note: I am long on calls for this into the summer.)
A good time to review the previous floor at 60.xx that we have been tracking for almost a year in $GILD. Here taking the latest misses in Q4 Earnings with a pinch of salt as the red carpet has been rolled out for Gild via China. Once again another buying opportunity given the latest progress around Phase III clinical trials: